Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis. Data from the STARK project, a prospective international, multicenter, cohort study (CROSBI ID 706098)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Kardenas Jaen, Karina ; Archibugi, Livia ; Poropat, Goran ; Korpela, Taija ; Capurso, Gabriele ; Maissoneuve, Patrick ; Aparicio, JR ; Cassellas, JA ; Arcidiacono, Paolo Giorgio ; Mariani, A ; Štimac, Davor ; Hauser, Goran ; Udd, A ; Kylanpaa L, Rainio, M ; Di Giulio, E ; Vanella, G ; Lohr, Matthias ; Valente, Roberto ; Arnelo, U ; De Pretis, Nicolo ; de-Madaria, Enrique
engleski
Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis. Data from the STARK project, a prospective international, multicenter, cohort study
Introduction: Acute Pancreatitis (AP) is the most frequent complication after Endoscopic Retrograde Cholangiopancreatography (ERCP). Some prophylactic strategies are the use of pancreatic stents or peri-procedural nonsteroidal anti-inflammatory drugs (NSAIDs). Statins are widely used lipid-lowering drugs. Recent studies suggest that chronic statin intake may be associated to a lower incidence of AP. Methods: Our aim is to investigate whether chronic statin and/or acetylsalicylic acid (ASA) intake is associated to a lower incidence of PEP. Stark project is an international, multicenter, prospective, cohort study, developed under the auspices of “Pancreas 2000”. Consecutive patients undergoing ERCP in seven european centers, older than 18, were included prospectively. Demographic and medical data were retrieved by anamnesis. Patients were followed-up to detect those with PEP. The sample size was estimated to be 1, 016 participants. A univariate analysis and multivariate analysis (binary logistic regression) were performed. Results: 1150 patients were included. Mean age was 68.4 years (SD 14.5). 561 (48.8%) patients were female. 70 patients developed post-ERCP-AP (PEP) (6.1%) ; 25 patients (8.1%) under chronic statin treatment versus 45 patients (5.4%) who do not (p= 0.086). Multivariate analysis showed an aOR of 1.679 (0.941-2.994), p 0.079 for PEP incidence in statin users. Regarding ASA consumption, 11 patients (6.6%) under ASA treatment versus 59 patients (6%) who were not consuming ASA, developed PEP (p= 0.753). Multivariate analysis showed an aOR of 1.017 (0.487-2.127), p=0.963 for PEP incidence among ASA users. Conclusion: Our data suggest that chronic statin and/or ASA intake isnt statistically associated to an increase incidence of PEP.
Statins ; post-ERCP pancreatitis ; prevention
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
S189-S190.
2019.
nije evidentirano
objavljeno
10.1016/j.pan.2019.07.033
Podaci o matičnoj publikaciji
Pancreatology
1424-3903
1424-3911
Podaci o skupu
XVI Pancreatology Spanish Association Meeting 2019
predavanje
19.09.2019-21.09.2019
Bilbao, Španjolska
Povezanost rada
Kliničke medicinske znanosti